Scholar Rock Holding (SRRK) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -35.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.76% |
| Dec 31, 2025 | -36.82% |
| Sep 30, 2025 | -58.52% |
| Jun 30, 2025 | -87.89% |
| Mar 31, 2025 | -31.40% |
| Dec 31, 2024 | -38.33% |
| Sep 30, 2024 | -47.56% |
| Jun 30, 2024 | -49.67% |
| Mar 31, 2024 | -40.29% |
| Dec 31, 2023 | -18.81% |
| Sep 30, 2023 | 0.43% |
| Jun 30, 2023 | 9.42% |
| Mar 31, 2023 | -484.29% |
| Dec 31, 2022 | -14.32% |
| Sep 30, 2022 | -18.30% |
| Jun 30, 2022 | -42.53% |
| Mar 31, 2022 | 74.52% |
| Dec 31, 2021 | -35.47% |
| Sep 30, 2021 | -56.99% |
| Jun 30, 2021 | -55.55% |
| Mar 31, 2021 | -53.76% |
| Dec 31, 2020 | -111.42% |
| Sep 30, 2020 | -38.07% |
| Jun 30, 2020 | -45.39% |
| Mar 31, 2020 | -51.19% |
| Dec 31, 2019 | 20.65% |
| Sep 30, 2019 | -52.27% |
| Jun 30, 2019 | 10.06% |
| Mar 31, 2019 | -29.80% |
| Dec 31, 2018 | -83.97% |
| Sep 30, 2018 | -89.06% |
| Jun 30, 2018 | -152.79% |